ArticleOncotarget2018

Preclinical study of a Kv11.1 potassium channel activator as antineoplastic approach for breast cancer.

Daniela F Fukushiro-Lopes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.